Biomarin Pharmaceutical News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

17.11.24	BioMarin : Real-World Evidence Supports Safety, Efficacy Of VOXZOGO In Children With Achondroplasia (RTTNews)
29.10.24	Biomarin Pharmaceutical Inc. Q3 Profit Increases, Beats Estimates (RTTNews)
18.09.24	BioMarin's CANOPY Trial Shows Positive Data About Voxzogo In Children With Achondroplasia (RTTNews)
01.09.24	Weekly Biotech Buzz: BMRN Cuts Jobs, FDA Approves New Mpox Vaccine, MRK Halts 2 Keytruda Studies (RTTNews)
05.08.24	Biomarin Pharmaceutical Inc. Q2 Profit Increases, Beats Estimates (RTTNews)
25.07.24	FDA Approves BioMarin Pharma's BRINEURA For Children Under 3 Years With CLN2 Disease (RTTNews)
17.06.24	BioMarin: Investigator-Led 5-yr Study Shows VOXZOGO Significantly Increases Bone Length (RTTNews)
07.06.24	BioMarin: 4-Yr Data From Phase 3 Hemophilia Gene Therapy Study Shows Safety, Efficacy Of ROCTAVIAN (RTTNews)
24.04.24	Biomarin Pharmaceutical Inc. Q1 Profit Increases, beats estimates (RTTNews)
22.02.24	Biomarin Pharmaceutical Inc. Q4 Earnings Summary (RTTNews)
20.12.23	BioMarin Announces Governance Enhancements and Value Creation Initiatives (PR Newswire)
28.11.23	BioMarin Pharma Reaches Agreement On Reimbursement Amount For ROCTAVIAN In Germany (RTTNews)
28.11.23	BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany (PR Newswire)
01.11.23	Biomarin Pharmaceutical Inc. Q3 Earnings Summary (RTTNews)
01.11.23	BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year (PR Newswire)
01.11.23	BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer (PR Newswire)
21.10.23	FDA Approves BioMarin Pharma's Voxzogo For Children Under 5 Years With Achondroplasia (RTTNews)
20.10.23	U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia (PR Newswire)
17.10.23	BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET (PR Newswire)
21.09.23	BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting (PR Newswire)
15.09.23	BioMarin Pharma: CHMP Adopts Positive Opinion To Expand Indication For VOXZOGO (RTTNews)
15.09.23	BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia (PR Newswire)
11.09.23	BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York (PR Newswire)
06.09.23	BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th (PR Newswire)
05.09.23	BioMarin to Participate in Three Upcoming Investor Conferences (PR Newswire)
30.08.23	BioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe (PR Newswire)
31.07.23	Biomarin Pharmaceutical Inc. Q2 Profit Increases, beats estimates (RTTNews)
31.07.23	BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date (PR Newswire)
12.07.23	BioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET (PR Newswire)
30.06.23	BioMarin Pharma Announces FDA Approval Of ROCTAVIAN Gene Therapy (RTTNews)
29.06.23	U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A (PR Newswire)
22.06.23	BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis ... (PR Newswire)
04.05.23	BioMarin to Participate in Bank of America 2023 Health Care Conference (PR Newswire)
26.04.23	Biomarin Pharmaceutical Inc. Q1 Profit Decreases, but beats estimates (RTTNews)
26.04.23	BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues (PR Newswire)
13.04.23	BioMarin to Host First Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, April 26, at 4:30pm ET (PR Newswire)
14.03.23	BioMarin to Share Updated Data at 2023 American College of Medical Genetics and Genomics (ACMG) Meeting Demonstrating Commitment to Understanding Long-Term Benefit of VOXZOGO® in Children with Ach... (PR Newswire)
07.03.23	FDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5 (PR Newswire)
07.03.23	BioMarin : FDA Extends Review Of BLA For Roctavian Gene Therapy For Severe Hemophilia A (RTTNews)
07.03.23	BioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A (PR Newswire)
02.03.23	BioMarin to Participate in Three Investor Conferences in March (PR Newswire)
28.02.23	Biotech Stocks Facing FDA Decision In March 2023 (RTTNews)
27.02.23	Biomarin Pharmaceutical Inc. Q4 Earnings Summary (RTTNews)
27.02.23	BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business (PR Newswire)
14.02.23	BioMarin to Participate Virtually at SVB Securities Global Biopharma Conference on February 16, 2023 (PR Newswire)
07.02.23	BioMarin to Host Fourth Quarter and Full-Year 2022 Financial Results Conference Call and Webcast on Monday, February 27, at 4:30 p.m. ET (PR Newswire)
08.01.23	BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Se... (PR Newswire)
04.01.23	BioMarin to Present at 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 10:30 am PT /1:30 pm ET, in San Francisco, CA (PR Newswire)
03.01.23	European Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2 (PR Newswire)
28.11.22	Form 4 1048477 (RSS)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

mehr

16.09.24		NASDAQ Composite aktuell: NASDAQ Composite schlussendlich im Minus
16.09.24		NASDAQ-Handel So entwickelt sich der NASDAQ Composite am Nachmittag
16.09.24		Anleger in New York halten sich zurück: NASDAQ Composite am Montagmittag schwächer
16.09.24		Verluste in New York: NASDAQ Composite verliert zum Start
06.08.24		Freundlicher Handel in New York: NASDAQ Composite zum Handelsende im Plus
06.08.24		Freundlicher Handel: NASDAQ Composite am Nachmittag freundlich
06.08.24		Handel in New York: NASDAQ Composite mittags mit grünem Vorzeichen
06.08.24		Börse New York in Grün: NASDAQ Composite zum Start des Dienstagshandels in Grün